(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.12%) $82.53
(0.89%) $2.05
(-0.52%) $2 345.50
(-1.07%) $27.37
(-0.32%) $958.40
(-0.19%) $0.933
(-0.28%) $10.99
(-0.53%) $0.796
(1.56%) $93.31
9.76% NZD 0.0900
Live Chart Being Loaded With Signals
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore...
Stats | |
---|---|
Dzisiejszy wolumen | 268 253 |
Średni wolumen | 368 332 |
Kapitalizacja rynkowa | 72.93M |
EPS | NZD0 ( 2023-11-21 ) |
Następna data zysków | ( NZD0 ) 2024-05-23 |
Last Dividend | NZD0 ( N/A ) |
Next Dividend | NZD0 ( N/A ) |
P/E | -2.25 |
ATR14 | NZD0 (0.00%) |
Pacific Edge Limited Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pacific Edge Limited Finanse
Annual | 2023 |
Przychody: | NZD19.62M |
Zysk brutto: | NZD9.60M (48.96 %) |
EPS: | NZD-0.0333 |
FY | 2023 |
Przychody: | NZD19.62M |
Zysk brutto: | NZD9.60M (48.96 %) |
EPS: | NZD-0.0333 |
FY | 2022 |
Przychody: | NZD11.45M |
Zysk brutto: | NZD4.56M (39.85 %) |
EPS: | NZD-0.0258 |
Financial Reports:
No articles found.
Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, the company is developing Cxcolorectal, a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej